风湿病患者中阿片类药物使用障碍及治疗接受度的描述性分析
基于All of Us研究项目,在37,282例风湿病患者中识别出1,502例(4%)阿片类药物使用障碍(OUD)患者。OUD患者更年轻、合并精神疾病和内科共病更多、急性期医疗使用更多,且既往阿片类处方和糖皮质激素使用比例更高,而改善病情抗风湿药(DMARDs)使用更少。仅14.5%的OUD患者接受阿片类药物使用障碍药物治疗(MOUDs)。
要点
- 风湿病患者中OUD患病率为4%,以年轻、合并精神疾病和共病者多见。
- OUD患者既往阿片类处方(75.7% vs 45.8%)和糖皮质激素使用更多,DMARDs使用更少。
- OUD患者中仅14.5%接受MOUDs,低于全国估计的25%。
核心结论
- 风湿病合并OUD患者具有独特的人口学和临床特征,包括DMARDs使用更少和急性期医疗使用更多。
- OUD患者中MOUDs接受率(14.5%)显著低于全国估计(25%)。
- 需要进一步研究以识别和解决这些患者药物可及性的障碍。
研究设计与样本
- 利用全国All of Us研究项目(第8版)数据,识别至少有两次SLE、RA、SpA或OA计费代码的个体。
- OUD通过至少一次阿片依赖或滥用代码识别,比较有无OUD患者的人口学、精神疾病、处方药物、共病和急性期医疗使用。
- 新MOUD使用定义为首次OUD代码后接受美沙酮、丁丙诺啡或纳曲酮处方,且既往无MOUD使用记录。
主要发现
- 37,282例风湿病患者中,1,502例(4%)有OUD。
- OUD患者更年轻,更可能有Medicaid保险、精神疾病和内科共病,以及更高的急性期医疗使用。
- OUD患者既往处方阿片类比例(75.7% vs 45.8%)和糖皮质激素使用更高,但生物制剂、靶向合成或传统DMARDs使用更少。
- 风湿病合并OUD患者中14.5%接受了MOUDs。
关键数值与推荐
- OUD识别标准:至少一次阿片依赖或滥用代码。
- 新MOUD使用:首次OUD代码后处方美沙酮、丁丙诺啡或纳曲酮,且既往无MOUD使用记录。
- 风湿病识别:至少两次SLE、RA、SpA或OA计费代码。
临床怎么用
- 风湿病合并OUD患者DMARDs使用较少而急性期医疗使用较多,提示需关注该人群的疾病管理。
- OUD患者中MOUDs接受率低(14.5%),临床应评估并促进MOUDs的可及性。
局限性
- 原文未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Opioid use disorder (OUD) is associated with high morbidity and mortality. We aimed to describe the characteristics of patients with osteoarthritis (OA), systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), or spondyloarthritis (SpA) who have OUD and to evaluate their uptake of medications for OUD (MOUDs). METHODS: Using the national All of Us Research Program (version 8), we identified individuals with at least two billing codes for SLE, RA, SpA, or OA. Patients with OUD were identified using at least one code for opioid dependence or abuse. We compared demographics, psychiatric disorders, prescription medications (opioids, glucocorticoids, and disease-modifying antirheumatic drugs [DMARDs]), comorbidities, and acute care use between patients with and without OUD. New MOUD use was defined by a prescription for methadone, buprenorphine, or naltrexone following the first OUD code in patients without prior MOUD use documented in available All of Us data. RESULTS: Of 37,282 patients with rheumatic conditions, 1,502 (4%) had OUD. Patients with versus without OUD were younger and were more likely to have Medicaid insurance, psychiatric and medical comorbidities, and higher acute care use. They were more likely to have received prior prescription opioids (75.7% vs 45.8%) and glucocorticoids but less likely to have used biologic, targeted synthetic, or conventional DMARDs. Of the patients with rheumatic diseases and OUD, 14.5% received MOUDs. CONCLUSION: Patients with rheumatic conditions and OUD exhibit distinct demographic and clinical characteristics including lower DMARD use and higher acute care use. MOUD uptake (14.5%) was significantly lower than national estimates (25%). Further research is needed to identify and address barriers to medication access in these patients.
引用
- Riegler JS, Santacroce L, Karlson EW, et al. Opioid Use Disorder and Treatment Uptake Among Patients With Rheumatic Conditions in the All of Us Research Program: A Descriptive Analysis. Arthritis Care Res (Hoboken). 2026. PMID: 42439302. doi:10.1002/acr.80114
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。